MindMaze Therapeutics Holding (HAM:V6M) PS Ratio: 5.59 (As of Sep. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:V6M MindMaze Therapeutics Holding SA HAM:V6M
6 GF Score
Price €0.15
! 2 Warning Signs
View Full Analysis

What is MindMaze Therapeutics Holding PS Ratio?

MindMaze Therapeutics Holding HAM:V6M -3.21% 6 PS Ratio is 5.59 as of Sep. 16, 2026. GuruFocus rates HAM:V6M with a GF Score™ of 6/100. The stock has 2 warning signs investors should review. Among 939 Biotechnology companies, MindMaze Therapeutics Holding ranks better than 57.72% on this metric.

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, MindMaze Therapeutics Holding's share price is €0.151. MindMaze Therapeutics Holding's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €0.03. Hence, MindMaze Therapeutics Holding's PS Ratio for today is 5.59.

The historical rank and industry rank for MindMaze Therapeutics Holding's PS Ratio or its related term are showing as below:

HAM:V6M' s PS Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 7
Current: 6.25

During the past 2 years, MindMaze Therapeutics Holding's highest PS Ratio was 7.00. The lowest was 0.00. And the median was 0.00.

HAM:V6M's PS Ratio is ranked better than
57.72% of 939 companies
in the Biotechnology industry
Industry Median: 9.21 vs HAM:V6M: 6.25

MindMaze Therapeutics Holding's Revenue per Sharefor the six months ended in Jun. 2026 was €0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €0.03.

During the past 12 months, the average Revenue per Share Growth Rate of MindMaze Therapeutics Holding was 700.00% per year.

Back to Basics: PS Ratio


MindMaze Therapeutics Holding  (HAM:V6M) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


MindMaze Therapeutics Holding PS Ratio Related Terms


MindMaze Therapeutics Holding PS Ratio Historical Data

* Premium members only.

The historical data trend for MindMaze Therapeutics Holding's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MindMaze Therapeutics Holding PS Ratio Chart

MindMaze Therapeutics Holding Annual Data
Trend Dec24 Dec25
PS Ratio
0.00 0.00

MindMaze Therapeutics Holding Semi-Annual Data
Dec24 Jun25 Dec25 Jun26
PS Ratio 0.00 0.00 0.00 0.00

HAM:V6M vs : PS Ratio Comparison

For the Biotechnology subindustry, MindMaze Therapeutics Holding's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MindMaze Therapeutics Holding PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindMaze Therapeutics Holding's PS Ratio distribution charts can be found below:

* The bar in red indicates where MindMaze Therapeutics Holding's PS Ratio falls into.


HAM:V6M
6GF Score
MindMaze Therapeutics Holding SA HAM:V6M
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindMaze Therapeutics Holding PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

MindMaze Therapeutics Holding's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.151/0.027
=5.59

MindMaze Therapeutics Holding's Share Price of today is €0.151.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. MindMaze Therapeutics Holding's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €0.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.

Frequently Asked Questions Learn more about PS Ratio →
What does a PS Ratio of 5.59 mean?
MindMaze Therapeutics Holding (HAM:V6M) has a PS Ratio of 5.59 as of Sep. 16, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on MindMaze Therapeutics Holding and its competitors. According to the industry distribution chart, MindMaze Therapeutics Holding ranks #397 out of 939 companies in the Biotechnology industry, placing it in the top 42.3%.
Is MindMaze Therapeutics Holding's PS Ratio too high?
MindMaze Therapeutics Holding's current PS Ratio is 5.59. The Biotechnology industry median PS Ratio is 9.21. MindMaze Therapeutics Holding's value of 5.59 is 39.3% below this industry median. Based on the distribution chart, MindMaze Therapeutics Holding ranks #397 out of 939 companies in the Biotechnology industry, which is above the industry midpoint. Overall, MindMaze Therapeutics Holding has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's PS Ratio compare to ?
According to the Biotechnology industry distribution chart, MindMaze Therapeutics Holding ranks #397 out of 939 companies for PS Ratio. This puts MindMaze Therapeutics Holding in the upper half of its industry. The industry median PS Ratio is 9.21. MindMaze Therapeutics Holding's value of 5.59 is 39.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.21, based on 939 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MindMaze Therapeutics Holding's current PS Ratio of 5.59 is 39.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on MindMaze Therapeutics Holding and its competitors. For the Biotechnology industry, the median PS Ratio is 9.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MindMaze Therapeutics Holding's current PS Ratio is 5.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (HAM:V6M) has a current PS Ratio of 5.59. The current PS Ratio is 5.59 and 39.3% below the Biotechnology industry median of 9.21. MindMaze Therapeutics Holding's overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For MindMaze Therapeutics Holding (HAM:V6M), the current PS Ratio is 5.59 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MindMaze Therapeutics Holding Business Description

Comparable Companies
Other Exchanges MMTXz:UKMMTX:Switzerland
Address Avenue de Secheron 15, Geneva, CHE, 1202
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
6GF Score

Get the complete analysis for HAM:V6M

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price